These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
272 related articles for article (PubMed ID: 1398742)
21. Generation of a small cell lung cancer variant resistant to lymphokine-activated killer (LAK) cells: association with resistance to a LAK cell-derived, cytostatic factor. Tachibana I; Watanabe M; Tanio Y; Hayashi S; Hosoe S; Saito S; Matsunashi M; Osaki T; Shigedo Y; Masuno T Cancer Res; 1992 Jun; 52(12):3310-6. PubMed ID: 1350752 [TBL] [Abstract][Full Text] [Related]
22. The specificity of lymphokine-activated killer (LAK) cells in vitro: fresh normal murine tissues are resistant to LAK-mediated lysis. Lefor AT; Rosenberg SA J Surg Res; 1991 Jan; 50(1):15-23. PubMed ID: 1987427 [TBL] [Abstract][Full Text] [Related]
23. Lymphokine-activated killer (LAK) cells. IV. Characterization of murine LAK effector subpopulations. Ballas ZK; Rasmussen W J Immunol; 1990 Jan; 144(1):386-95. PubMed ID: 2104892 [TBL] [Abstract][Full Text] [Related]
24. Induction of murine lymphokine-activated killer-like cells by Corynebacterium parvum (C. parvum) in vitro: lysis of tumor cells and macrophages by C. parvum-induced killer cells. Chen MF; Suzuki H; Yano S Anticancer Res; 1992; 12(2):451-6. PubMed ID: 1580562 [TBL] [Abstract][Full Text] [Related]
25. VLA-6 (CDw49f) is an important adhesion molecule in NK cell-mediated cytotoxicity following autologous or allogeneic bone marrow transplantation. Lowdell MW; Shamim F; Hamon M; Macdonald ID; Prentice HG Exp Hematol; 1995 Dec; 23(14):1530-4. PubMed ID: 8542943 [TBL] [Abstract][Full Text] [Related]
26. Analysis of the murine lymphokine-activated killer (LAK) cell phenomenon: dissection of effectors and progenitors into NK- and T-like cells. Kalland T; Belfrage H; Bhiladvala P; Hedlund G J Immunol; 1987 Jun; 138(11):3640-5. PubMed ID: 3495566 [TBL] [Abstract][Full Text] [Related]
27. Sensitivity of ovarian tumor cells to effector cells generated by various biological response modifiers. Nio Y; Zighelboim J; Berek JS; Bonavida B Nat Immun Cell Growth Regul; 1990; 9(4):283-96. PubMed ID: 2215516 [TBL] [Abstract][Full Text] [Related]
28. Target cell membrane modification and susceptibility to lymphokine-activated killer cell-mediated lysis. II. Sodium periodate has a differential effect on the lysis of human and murine tumor cells. Midis GP; Gupta VK; Fabian DF; Lefor AT J Surg Res; 1994 Feb; 56(2):146-54. PubMed ID: 8121171 [TBL] [Abstract][Full Text] [Related]
29. Protection of cultured human monocytes from lymphokine-activated killer-mediated lysis by IFN-gamma. Blanchard DK; Djeu JY J Immunol; 1988 Dec; 141(11):4067-73. PubMed ID: 2460557 [TBL] [Abstract][Full Text] [Related]
31. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity. Kawase I; Komuta K; Hara H; Inoue T; Hosoe S; Ikeda T; Shirasaka T; Yokota S; Tanio Y; Masuno T Cancer Res; 1988 Mar; 48(5):1173-9. PubMed ID: 3257715 [TBL] [Abstract][Full Text] [Related]
32. Correlation of class I MHC antigen levels on some human tumor cell lines with susceptibility to LAK cells and performance in cold target inhibition assays. Haridas V; Saxena RK Cell Immunol; 1995 Apr; 161(2):256-61. PubMed ID: 7697736 [TBL] [Abstract][Full Text] [Related]
33. Murine trophoblast can be killed by lymphokine-activated killer cells. Drake BL; Head JR J Immunol; 1989 Jul; 143(1):9-14. PubMed ID: 2499634 [TBL] [Abstract][Full Text] [Related]
34. Target cell membrane modification and susceptibility to lymphokine activated killer cell mediated lysis. I. Trinitrophenyl has no effect on murine normal cells and tumors. Lefor AT J Surg Res; 1991 Oct; 51(4):316-23. PubMed ID: 1921371 [TBL] [Abstract][Full Text] [Related]
35. Activated endothelial cells resist lymphokine-activated killer cell-mediated injury. Possible role of induced cytokines in limiting capillary leak during IL-2 therapy. Mier JW; Brandon EP; Libby P; Janicka MW; Aronson FR J Immunol; 1989 Oct; 143(7):2407-14. PubMed ID: 2528594 [TBL] [Abstract][Full Text] [Related]
36. Generation of lymphokine-activated killer cells in strain 2 guinea pigs and their use in the therapy of L2C, an acute B-cell leukemia. Gregg EO; Gregg IC; Green I Cancer Res; 1987 Feb; 47(3):723-9. PubMed ID: 3492265 [TBL] [Abstract][Full Text] [Related]
37. Enhancement of murine lymphokine-activated killer cell activity by retinoic acid. Lin TH; Chu TM Cancer Res; 1990 May; 50(10):3013-8. PubMed ID: 1970751 [TBL] [Abstract][Full Text] [Related]
38. [Apoptosis of tumor cells in lectin-dependent lymphokine-activated killer cell-mediated cytotoxicity]. Dong H; Xing R; Guo L Zhonghua Zhong Liu Za Zhi; 1995 Jul; 17(4):245-8. PubMed ID: 7587887 [TBL] [Abstract][Full Text] [Related]
39. Interleukin 2 protects hairy leukemic cells from lymphokine-activated killer cell-mediated cytotoxicity. Reiter Z; Taylor MW Cancer Res; 1993 Aug; 53(15):3555-60. PubMed ID: 7687924 [TBL] [Abstract][Full Text] [Related]
40. Resistance of HER2/neu-overexpressing tumor targets to lymphokine-activated-killer-cell-mediated lysis: evidence for deficiency of binding and post-binding events. Fady C; Gardner A; Gera JF; Lichtenstein A Cancer Immunol Immunother; 1993 May; 36(5):307-14. PubMed ID: 8097427 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]